A virtual reality craving study in tobacco addiction: The role of non-pharmacological support in tobacco detox therapy.

addiction craving nicotine tobacco virtual reality

Journal

Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006

Informations de publication

Date de publication:
2022
Historique:
received: 09 05 2022
accepted: 06 09 2022
entrez: 31 10 2022
pubmed: 1 11 2022
medline: 1 11 2022
Statut: epublish

Résumé

Nicotine addiction is a widespread, worldwide epidemic, causing six million deaths per year. A large variety of treatments for smoking cessation are currently available, including Cytisine, which is a promising drug due to its low cost and high safety levels. Notwithstanding the important amount of research on tobacco addiction treatments, smoking remains one of the most difficult substance use disorders to treat, probably also due to the fact that pharmacological treatment often overlooks other maintaining factors in this addiction, such as sensory impact and cue reactivity. To address this gap in both treatment protocols and scientific literature, we propose a study protocol in which we will compare the effects of combining Cytisine with Nirdosh, a herbal tobacco substitute, to Cytisine only in two groups of patients (C + N and C) who will also undergo exposure to four different virtual reality settings that will assess the importance of environmental cues. We will further assess mood and craving in the two samples, and include a control group taken from the general population. We expect the C + N group to report a more positive mood and a lower sensitivity to tobacco-related environmental cues.

Identifiants

pubmed: 36311510
doi: 10.3389/fpsyt.2022.940100
pmc: PMC9606784
doi:

Types de publication

Journal Article

Langues

eng

Pagination

940100

Informations de copyright

Copyright © 2022 Zamboni, Campagnari, Giordano, Fusina, Carli, Congiu, Barbon, Melchiori, Casari, Tedeschi, Vesentin, Verlato, Infante and Lugoboni.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Arch Gen Psychiatry. 1961 Jun;4:561-71
pubmed: 13688369
Exp Clin Psychopharmacol. 2003 Aug;11(3):218-227
pubmed: 12940501
Addiction. 2003 Nov;98(11):1547-61
pubmed: 14616181
J Consult Clin Psychol. 1988 Dec;56(6):893-7
pubmed: 3204199
Nicotine Tob Res. 2014 Dec;16(12):1541-8
pubmed: 25082832
Arch Gen Psychiatry. 1991 Jan;48(1):52-9
pubmed: 1984762
Pharmacol Rep. 2006 Nov-Dec;58(6):777-98
pubmed: 17220536
J Neurochem. 2014 Jul;130(2):185-98
pubmed: 24661093
Addiction. 2008 Jan;103(1):146-54
pubmed: 18028247
Behav Pharmacol. 2010 Mar;21(2):144-52
pubmed: 20168213
Arch Toxicol Suppl. 1980;4:312-4
pubmed: 6933924
Prog Clin Biol Res. 1988;261:63-94
pubmed: 3289011
Nicotine Tob Res. 2012 Jan;14(1):75-8
pubmed: 22025545
Chronobiol Int. 1994 Oct;11(5):320-31
pubmed: 7828215
Cochrane Database Syst Rev. 2019 Feb 13;2:CD003999
pubmed: 30758045
N Engl J Med. 2011 Sep 29;365(13):1193-200
pubmed: 21991893
J Abnorm Psychol. 2010 Feb;119(1):248-53
pubmed: 20141262
Pharmacol Biochem Behav. 2009 Jan;91(3):461-7
pubmed: 18817808
Nicotine Tob Res. 2004 Dec;6(6):941-59
pubmed: 15801569
Int J Environ Res Public Health. 2014 Apr 22;11(4):4356-73
pubmed: 24758891
Drug Alcohol Depend. 1993 Jan;31(2):131-8
pubmed: 8436059
J Consult Clin Psychol. 1996 Oct;64(5):993-1002
pubmed: 8916628
Front Psychol. 2019 Feb 04;10:158
pubmed: 30778320
Psychopharmacology (Berl). 1996 Sep;127(1):55-62
pubmed: 8880944
Nicotine Tob Res. 2006 Oct;8(5):661-9
pubmed: 17008193
J Med Chem. 2005 May 19;48(10):3474-7
pubmed: 15887955
Addiction. 2016 Nov;111(11):1895-1898
pubmed: 27426482
Exp Clin Psychopharmacol. 2008 Jun;16(3):207-14
pubmed: 18540780
Br J Addict. 1991 Sep;86(9):1119-27
pubmed: 1932883
Addiction. 2019 Nov;114(11):1951-1969
pubmed: 31240783
Interdiscip Toxicol. 2010 Mar;3(1):15-20
pubmed: 21217866
Brain Res Brain Res Rev. 2005 Feb;48(1):74-97
pubmed: 15708629
Curr Med Res Opin. 2007 Apr;23(4):793-801
pubmed: 17407636
BMJ. 2013 Aug 23;347:f5198
pubmed: 23974638
JAMA. 2006 Jul 5;296(1):47-55
pubmed: 16820546
Forensic Sci Int. 2009 Apr 15;186(1-3):e1-4
pubmed: 19217730
N Engl J Med. 2014 Dec 18;371(25):2353-62
pubmed: 25517706
Addiction. 2005 Mar;100(3):387-96
pubmed: 15733252
Addiction. 2005 Jun;100(6):837-51
pubmed: 15918814
Arch Intern Med. 2006 Aug 14-28;166(15):1553-9
pubmed: 16908787
Thorax. 2013 Nov;68(11):1037-42
pubmed: 23404838

Auteurs

Lorenzo Zamboni (L)

Unit of Addiction Medicine, Department of Internal Medicine, G.B. Rossi Hospital, Verona, Italy.
Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.

Simone Campagnari (S)

Unit of Addiction Medicine, Department of Internal Medicine, G.B. Rossi Hospital, Verona, Italy.

Rosaria Giordano (R)

Unit of Addiction Medicine, Department of Internal Medicine, G.B. Rossi Hospital, Verona, Italy.
Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.

Francesca Fusina (F)

Department of General Psychology, University of Padova, Padua, Italy.
Padova Neuroscience Center, University of Padova, Padua, Italy.

Silvia Carli (S)

Unit of Addiction Medicine, Department of Internal Medicine, G.B. Rossi Hospital, Verona, Italy.
Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.

Alessio Congiu (A)

Unit of Addiction Medicine, Department of Internal Medicine, G.B. Rossi Hospital, Verona, Italy.

Isabella Barbon (I)

Unit of Addiction Medicine, Department of Internal Medicine, G.B. Rossi Hospital, Verona, Italy.

Silvia Melchiori (S)

Unit of Addiction Medicine, Department of Internal Medicine, G.B. Rossi Hospital, Verona, Italy.

Rebecca Casari (R)

Unit of Addiction Medicine, Department of Internal Medicine, G.B. Rossi Hospital, Verona, Italy.

Elisa Tedeschi (E)

Unit of Addiction Medicine, Department of Internal Medicine, G.B. Rossi Hospital, Verona, Italy.

Roberta Vesentin (R)

Diagnostics and Public Health-Unit of Epidemiology and Medical Statistics, University of Verona, Verona, Italy.

Giuseppe Verlato (G)

Diagnostics and Public Health-Unit of Epidemiology and Medical Statistics, University of Verona, Verona, Italy.

Maurizio Valentino Infante (MV)

Thoracic Surgery Department, University and Hospital Trust-Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Fabio Lugoboni (F)

Unit of Addiction Medicine, Department of Internal Medicine, G.B. Rossi Hospital, Verona, Italy.

Classifications MeSH